Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study | Zendy

Ines Van den Bosch | Zendy; Thomas Bouillon | Zendy; Peter Verhamme | Zendy; Thomas Vanassche | Zendy; Marc Jacquemin | Zendy; Maarten Coemans | Zendy; Dirk Kuypers | Zendy; Björn Meijers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study

Author(s) -

Ines Van den Bosch,

Thomas Bouillon,

Peter Verhamme,

Thomas Vanassche,

Marc Jacquemin,

Maarten Coemans,

Dirk Kuypers,

Björn Meijers

Publication year - 2020

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfaa351

Subject(s) - medicine , apixaban , dialysis , dosing , cmax , pharmacokinetics , population , hemodialysis , urology , anesthesia , pharmacology , atrial fibrillation , warfarin , rivaroxaban , environmental health

Apixaban, a direct oral anticoagulant inhibiting factor Xa, has been proven to reduce the risk of atrial fibrillation-related stroke and thromboembolism in patients with mild to moderate renal insufficiency. Patients on renal replacement therapy, however, were excluded from randomized controlled trials. Therefore, uncertainty remains concerning benefits, dosing and timing of intake in haemodialysis population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research